Botulinum neurotoxin (BoNT) is a toxin which is produced by the bacteria Clostridium botulinum. It belongs to the BoNT/A group of clostridial toxin family and is among the most powerful and deadly toxins known to mankind. BoNT acts by blocking the release of the neurotransmitter acetylcholine from presynaptic nerve terminals, thus causing flaccid paralysis of the muscle. BoNT has been used for therapeutic purposes as a muscle relaxant since the end of the last century. It is used to treat a variety of medical conditions such as cervical dystonia, blepharospasm, strabismus, and facial wrinkles. BoNT injections have become increasingly popular due to their success in reducing the appearance of wrinkles and treating muscle spasms. BoNT is available in various forms and formulations. Its potential medical applications are expanding from its traditional therapeutic uses to new areas in clinical research such as drug delivery systems, gene therapy, and neuroprotection. BoNT has also been proposed as a biological weapon due to its high toxicity and persistence in inhaled air. BoNT is a potent toxin and can be fatal in large doses. Moreover, it is resistant to traditional antiviral and antimicrobial therapies. A variety of techniques are used to protect against BoNT exposure including immunization, physical barriers, and a combination of both. Vaccines are available to provide protection from some of the BoNT serotypes. In conclusion, BoNT is a highly potent toxin with great potential in the medical field and has been used for a variety of medical conditions such as neurological disorders and wrinkles. Of course, it must be handled with extreme caution due to its immense toxicity and potential to be used as a biological weapon. Vaccines are available to provide protection from some of the BoNT serotypes and other measures can be taken to protect against exposure.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States